Edwards says recently, Summit reported that Phase II trials showed that antibiotic Ridinilazole can kill C.difficile infections while preserving healthy microorganisms in the gastrointestinal tract. Summit remains on track to deliver Phase III data for its antibiotic Ridinilazole in the second half of 2021.
Summit Therapeutics CEO says anti microbial resistance will be as big a problem as climate change
Quick facts: Summit Therapeutics PLC
Price: 20.47 GBX
Market Cap: £68.76 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE